Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 372 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Glucagon-like peptide-1 analogues: An overview

Gupta Vishal

Year : 2013| Volume: 17| Issue : 3 | Page no: 413-421

   This article has been cited by
 
1 Antidiabetic therapies and male reproductive function: where do we stand?
R S Tavares,S Escada-Rebelo,A F Silva,M I Sousa,J Ramalho-Santos,S Amaral
Reproduction. 2018; 155(1): R13
[Pubmed]  [Google Scholar] [DOI]
2 Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core
Kellie D. Nance,Emily L. Days,C. David Weaver,Anastasia Coldren,Tiffany D. Farmer,Hyekyung P. Cho,Colleen M. Niswender,Anna L. Blobaum,Kevin D. Niswender,Craig W. Lindsley
Journal of Medicinal Chemistry. 2017;
[Pubmed]  [Google Scholar] [DOI]
3 Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee,Dong Yun Lee
Annals of Pediatric Endocrinology & Metabolism. 2017; 22(1): 15
[Pubmed]  [Google Scholar] [DOI]
4 The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy. 2017;
[Pubmed]  [Google Scholar] [DOI]
5 Gold nanoparticles as an efficient drug delivery system for GLP-1 peptides
Magdalena Pérez-Ortiz,Claudio Zapata-Urzúa,Gerardo A. Acosta,Alejandro Álvarez-Lueje,Fernando Albericio,Marcelo J. Kogan
Colloids and Surfaces B: Biointerfaces. 2017; 158: 25
[Pubmed]  [Google Scholar] [DOI]
6 Lixisenatide as add-on treatment among patients with different ß-cell function levels as assessed by HOMA-ß index
Riccardo C. Bonadonna,Lawrence Blonde,Mikhail Antsiferov,Rachele Berria,Pierre Gourdy,Mensud Hatunic,Viswanathan Mohan,Michael Horowitz
Diabetes/Metabolism Research and Reviews. 2017; : e2897
[Pubmed]  [Google Scholar] [DOI]
7 Peptibodies: An elegant solution for a long-standing problem
Marco Cavaco,Miguel A. R. B. Castanho,Vera Neves
Biopolymers. 2017; : e23095
[Pubmed]  [Google Scholar] [DOI]
8 Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+–XO–ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways
Ying Zhang,Hao Zhou,Wenbo Wu,Chen Shi,Shunying Hu,Tong Yin,Qiang Ma,Tianwen Han,Yingqian Zhang,Feng Tian,Yundai Chen
Free Radical Biology and Medicine. 2016; 95: 278
[Pubmed]  [Google Scholar] [DOI]
9 Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation
Harika Meduru,Yeng-Tseng Wang,Jeffrey Tsai,Yu-Ching Chen
International Journal of Molecular Sciences. 2016; 17(6): 920
[Pubmed]  [Google Scholar] [DOI]
10 Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice
L M McShane,N Irwin,D O’Flynn,Z J Franklin,C M Hewage,F P M O’Harte
Journal of Endocrinology. 2016; 229(3): 319
[Pubmed]  [Google Scholar] [DOI]
11 Albiglutide: a unique GLP-1 receptor agonist
Marc S. Rendell
Expert Opinion on Biological Therapy. 2016; 16(12): 1557
[Pubmed]  [Google Scholar] [DOI]
12 A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Sheena Kayaniyil,Greta Lozano-Ortega,Heather A. Bennett,Kristina Johnsson,Alka Shaunik,Susan Grandy,Bernt Kartman
Diabetes Therapy. 2016;
[Pubmed]  [Google Scholar] [DOI]
13 Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Markolf Hanefeld,Denis Raccah,Louis Monnier
Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
14 Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions
Amit Lakhanpal,Ernest Brahn
Clinical Rheumatology. 2016; 35(12): 2869
[Pubmed]  [Google Scholar] [DOI]
15 Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé ?
J.-F. Blicklé
Médecine des Maladies Métaboliques. 2016; 10(6): 574
[Pubmed]  [Google Scholar] [DOI]
16 Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
Ali A Rizvi,Angelo Maria Patti,Rosaria Vincenza Giglio,Dragana Nikolic,Antonella Amato,Noor Al-Busaidi,Khalid Al-Rasadi,Maurizio Soresi,Maciej Banach,Giuseppe Montalto,Manfredi Rizzo
Expert Opinion on Biological Therapy. 2015; 15(10): 1391
[Pubmed]  [Google Scholar] [DOI]
17 Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes
Nigel Irwin,Steven Patterson,Martin de Kort,R. Charlotte Moffett,Jeffry A. J. Wisse,Wim H. A. Dokter,Ebo S. Bos,André M. M. Miltenburg,Peter R. Flatt
ChemMedChem. 2015; 10(8): 1424
[Pubmed]  [Google Scholar] [DOI]
18 Incretin-based therapies for obesity treatment
Aline Haas de Mello,Morgana Prá,Larissa Colonetti Cardoso,Rosiane de Bona Schraiber,Gislaine Tezza Rezin
Metabolism. 2015; 64(9): 967
[Pubmed]  [Google Scholar] [DOI]
19 Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography–tandem mass spectrometry
Xiaoyan Zhu,Jingjing Liu,Jie Wu,Rongyue Cao,Taiming Li
Journal of Chromatography B. 2014; 967: 50
[Pubmed]  [Google Scholar] [DOI]
20 Enhanced survival of human mesenchymal stem cells following co-delivery with glucagon-like peptide-1 analogue in fibrin gel
Hyerim Jin,Woo Jung Lee,Soongdong Lee,TacGhee Yi,Sun Uk Song,Gayong Shim,Yu-Kyoung Oh
Journal of Pharmaceutical Investigation. 2014;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article